HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pitfalls in the use of surrogate markers for human immunodeficiency virus disease: further evidence on pathogenesis.

Abstract
The administration of drugs to human immunodeficiency virus patients with a pronounced CD4+ T lymphocytopenia may cause non-specific binding of the murine antibodies used in flow cytometry. This has produced spurious reports of early thymocytes in the circulating blood of human immunodeficiency virus-infected individuals following treatment with an anti-adhesion monoclonal mouse antibody (Cytolin+). Recent clinical experience with Cytolin+ confirms the pathogenic role of leukocyte adhesion pathways in human immunodeficiency virus infection. However, this experience also illustrates how comparisons of viral burden can be misleading. For nine patients with low CD4 counts, Cytolin+ alone reduced the mean ribonucleic acid-polymerase chain reaction by 0.45 log to 39 800 particles per mL. Ten patients with more advanced disease added Cytolin+ to an established regimen of standard antiretroviral drugs. Their mean polymerase chain reaction was only reduced by 0.2 log to 91 501. Yet, 67% of the former patients experienced a major clinical event within seven months, whereas the latter patients remained stable during this time.
AuthorsA D Allen, T Hillis, P Vidikan, V Beer
JournalMedical hypotheses (Med Hypotheses) Vol. 47 Issue 1 Pg. 27-30 (Jul 1996) ISSN: 0306-9877 [Print] United States
PMID8819112 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Biomarkers
  • Cytolin+
Topics
  • Animals
  • Antibodies, Monoclonal (therapeutic use)
  • Artifacts
  • Biomarkers
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes (immunology)
  • Flow Cytometry (methods)
  • HIV (isolation & purification)
  • HIV Infections (immunology, therapy)
  • Humans
  • Lymphopenia
  • Mice
  • Polymerase Chain Reaction (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: